Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2021

Open Access 01-12-2021 | Sertraline | Research

Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment

Authors: Di Ye, Huanji Xu, Hongwei Xia, Chenliang Zhang, Qiulin Tang, Feng Bi

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Login to get access

Abstract

Background

Serotonin signaling has been associated with tumorigenesis and tumor progression. Targeting the serotonin transporter to block serotonin cellular uptake confers antineoplastic effects in various tumors, including colon cancer. However, the antineoplastic mechanism of serotonin transporter inhibition and serotonin metabolism alterations in the absence of serotonin transporter have not been elucidated, especially in colon cancer, which might limit anti-tumor effects associating with targeting serotonin transporter.

Methods

The promotion in the uptake and catabolism of extracellular tryptophan and targeting serotonin transporter was detected by using quantitative reverse-transcription polymerase chain reaction, western blotting and liquid chromatography tandem mass spectrometry. Western blotting Immunoprecipitation and immunofluorescence was utilized to research the serotonylation of mTOR by serotonin and serotonin transporter inhibition. The primary mouse model, homograft model and tissue microarry was used to explore the tryptophan pathway in colon cancer. The cell viability assay, western blotting, xenograft and primary colon cancer mouse model were used to identify whether the combination of sertraline and tryptophan restriction had a synergistic effect.

Results

Targeting serotonin transporter through genetic ablation or pharmacological inhibition in vitro and in vivo induced a compensatory effect by promoting the uptake and catabolism of extracellular tryptophan in colon cancer. Mechanistically, targeting serotonin transporter suppressed mTOR serotonylation, leading to mTOR inactivation and increased tryptophan uptake. In turn, this process promoted serotonin biosynthesis and oncogenic metabolite kynurenine production through enhanced tryptophan catabolism. Tryptophan deprivation, or blocking its uptake by using trametinib, a MEK inhibitor, can sensitize colon cancer to selective serotonin reuptake inhibitors.

Conclusions

The present study elucidated a novel feedback mechanism involved in the regulation of serotonin homeostasis and suggested innovative strategies for selective serotonin reuptake inhibitors-based treatment of colon cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Walther D, Peter J, Bashammakh S, Hörtnagl H, Voits M, Fink H, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science (New York, NY). 2003;299(5603):76.CrossRef Walther D, Peter J, Bashammakh S, Hörtnagl H, Voits M, Fink H, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science (New York, NY). 2003;299(5603):76.CrossRef
2.
go back to reference Kannen V, Bader M, Sakita J, Uyemura S, Squire J. The dual role of serotonin in colorectal Cancer. Trends Endocrinol Metab. 2020;31(8):611–25.PubMedCrossRef Kannen V, Bader M, Sakita J, Uyemura S, Squire J. The dual role of serotonin in colorectal Cancer. Trends Endocrinol Metab. 2020;31(8):611–25.PubMedCrossRef
3.
go back to reference Nocito A, Dahm F, Jochum W, Jang J, Georgiev P, Bader M, et al. Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res. 2008;68(13):5152–8.PubMedCrossRef Nocito A, Dahm F, Jochum W, Jang J, Georgiev P, Bader M, et al. Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res. 2008;68(13):5152–8.PubMedCrossRef
4.
go back to reference Sakita J, Bader M, Santos E, Garcia S, Minto S, Alenina N, et al. Serotonin synthesis protects the mouse colonic crypt from DNA damage and colorectal tumorigenesis. J Pathol. 2019;249(1):102–13.PubMedCrossRef Sakita J, Bader M, Santos E, Garcia S, Minto S, Alenina N, et al. Serotonin synthesis protects the mouse colonic crypt from DNA damage and colorectal tumorigenesis. J Pathol. 2019;249(1):102–13.PubMedCrossRef
5.
go back to reference Tutton P, Barkla D. The influence of serotonin on the mitotic rate in the colonic crypt epithelium and in colonic adenocarcinoma in rats. Clin Exp Pharmacol Physiol. 1978;5(1):91–4.PubMedCrossRef Tutton P, Barkla D. The influence of serotonin on the mitotic rate in the colonic crypt epithelium and in colonic adenocarcinoma in rats. Clin Exp Pharmacol Physiol. 1978;5(1):91–4.PubMedCrossRef
6.
7.
go back to reference Peters M, Meijer C, Fehrmann R, Walenkamp A, Kema I, de Vries E, et al. Serotonin and dopamine receptor expression in solid Tumours including rare cancers. Pathol Oncol Res. 2020;26(3):1539–47.PubMedCrossRef Peters M, Meijer C, Fehrmann R, Walenkamp A, Kema I, de Vries E, et al. Serotonin and dopamine receptor expression in solid Tumours including rare cancers. Pathol Oncol Res. 2020;26(3):1539–47.PubMedCrossRef
8.
go back to reference Xia Y, Wang D, Zhang N, Wang Z, Pang L. Plasma serotonin level is a predictor for recurrence and poor prognosis in colorectal cancer patients. J Clin Lab Anal. 2018;32(2):e22263.CrossRef Xia Y, Wang D, Zhang N, Wang Z, Pang L. Plasma serotonin level is a predictor for recurrence and poor prognosis in colorectal cancer patients. J Clin Lab Anal. 2018;32(2):e22263.CrossRef
9.
go back to reference Walther D, Peter J, Winter S, Höltje M, Paulmann N, Grohmann M, et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell. 2003;115(7):851–62.PubMedCrossRef Walther D, Peter J, Winter S, Höltje M, Paulmann N, Grohmann M, et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell. 2003;115(7):851–62.PubMedCrossRef
10.
go back to reference Paulmann N, Grohmann M, Voigt JP, Bert B, Vowinckel J, Bader M, et al. Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS Biol. 2009;7(10):e1000229.PubMedPubMedCentralCrossRef Paulmann N, Grohmann M, Voigt JP, Bert B, Vowinckel J, Bader M, et al. Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS Biol. 2009;7(10):e1000229.PubMedPubMedCentralCrossRef
11.
go back to reference Farrelly L, Thompson R, Zhao S, Lepack A, Lyu Y, Bhanu N, et al. Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3. Nature. 2019;567(7749):535–9.PubMedPubMedCentralCrossRef Farrelly L, Thompson R, Zhao S, Lepack A, Lyu Y, Bhanu N, et al. Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3. Nature. 2019;567(7749):535–9.PubMedPubMedCentralCrossRef
12.
go back to reference Walther D, Bader M. A unique central tryptophan hydroxylase isoform. Biochem Pharmacol. 2003;66(9):1673–80.PubMedCrossRef Walther D, Bader M. A unique central tryptophan hydroxylase isoform. Biochem Pharmacol. 2003;66(9):1673–80.PubMedCrossRef
13.
go back to reference Patel M, Dalvi P, Gokulgandhi M, Kesh S, Kohli T, Pal D, et al. Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells. Int J Pharm. 2013;443:245–53.PubMedCrossRef Patel M, Dalvi P, Gokulgandhi M, Kesh S, Kohli T, Pal D, et al. Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells. Int J Pharm. 2013;443:245–53.PubMedCrossRef
14.
go back to reference Cibrian D, Saiz M, de la Fuente H, Sánchez-Díaz R, Moreno-Gonzalo O, Jorge I, et al. CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-dependent secretion of IL-22 in psoriasis. Nat Immunol. 2016;17(8):985–96.PubMedCrossRef Cibrian D, Saiz M, de la Fuente H, Sánchez-Díaz R, Moreno-Gonzalo O, Jorge I, et al. CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-dependent secretion of IL-22 in psoriasis. Nat Immunol. 2016;17(8):985–96.PubMedCrossRef
15.
go back to reference Timosenko E, Ghadbane H, Silk J, Shepherd D, Gileadi U, Howson L, et al. Nutritional stress induced by tryptophan-degrading enzymes results in ATF4-dependent reprogramming of the amino acid transporter profile in tumor cells. Cancer Res. 2016;76(21):6193–204.PubMedPubMedCentralCrossRef Timosenko E, Ghadbane H, Silk J, Shepherd D, Gileadi U, Howson L, et al. Nutritional stress induced by tryptophan-degrading enzymes results in ATF4-dependent reprogramming of the amino acid transporter profile in tumor cells. Cancer Res. 2016;76(21):6193–204.PubMedPubMedCentralCrossRef
16.
go back to reference Ye Z, Yue L, Shi J, Shao M, Wu T. Role of IDO and TDO in cancers and related diseases and the therapeutic implications. J Cancer. 2019;10(12):2771–82.PubMedPubMedCentralCrossRef Ye Z, Yue L, Shi J, Shao M, Wu T. Role of IDO and TDO in cancers and related diseases and the therapeutic implications. J Cancer. 2019;10(12):2771–82.PubMedPubMedCentralCrossRef
17.
go back to reference Löb S, Königsrainer A, Rammensee H, Opelz G, Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer. 2009;9(6):445–52.PubMedCrossRef Löb S, Königsrainer A, Rammensee H, Opelz G, Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer. 2009;9(6):445–52.PubMedCrossRef
18.
go back to reference Metz R, Duhadaway J, Kamasani U, Laury-Kleintop L, Muller A, Prendergast G. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67(15):7082–7.PubMedCrossRef Metz R, Duhadaway J, Kamasani U, Laury-Kleintop L, Muller A, Prendergast G. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67(15):7082–7.PubMedCrossRef
19.
go back to reference Xu H, Zhou S, Xia H, Yu H, Tang Q, Bi F. MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells. Cell Death Differ. 2019;26(11):2400–15.PubMedPubMedCentralCrossRef Xu H, Zhou S, Xia H, Yu H, Tang Q, Bi F. MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells. Cell Death Differ. 2019;26(11):2400–15.PubMedPubMedCentralCrossRef
20.
go back to reference Neufert C, Becker C, Neurath M. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc. 2007;2(8):1998–2004.PubMedCrossRef Neufert C, Becker C, Neurath M. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc. 2007;2(8):1998–2004.PubMedCrossRef
21.
go back to reference Rahbek-Clemmensen T, Bay T, Eriksen J, Gether U, Jørgensen T. The serotonin transporter undergoes constitutive internalization and is primarily sorted to late endosomes and lysosomal degradation. J Biol Chem. 2014;289(33):23004–19. Rahbek-Clemmensen T, Bay T, Eriksen J, Gether U, Jørgensen T. The serotonin transporter undergoes constitutive internalization and is primarily sorted to late endosomes and lysosomal degradation. J Biol Chem. 2014;289(33):23004–19.
22.
go back to reference Côté F, Thévenot E, Fligny C, Fromes Y, Darmon M, Ripoche M, et al. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci U S A. 2003;100(23):13525–30.PubMedPubMedCentralCrossRef Côté F, Thévenot E, Fligny C, Fromes Y, Darmon M, Ripoche M, et al. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci U S A. 2003;100(23):13525–30.PubMedPubMedCentralCrossRef
24.
go back to reference Greig C, Zhang L, Cowles R. Potentiated serotonin signaling in serotonin re-uptake transporter knockout mice increases enterocyte mass and small intestinal absorptive function. Physiol Rep. 2019;7(21):e14278.PubMedPubMedCentralCrossRef Greig C, Zhang L, Cowles R. Potentiated serotonin signaling in serotonin re-uptake transporter knockout mice increases enterocyte mass and small intestinal absorptive function. Physiol Rep. 2019;7(21):e14278.PubMedPubMedCentralCrossRef
25.
go back to reference Park C, Armenia S, Shaughnessy M, Greig C, Cowles R. Potentiation of serotonin signaling leads to increased carbohydrate and lipid absorption in the murine small intestine. J Pediatr Surg. 2019;54(6):1245–9.PubMedCrossRef Park C, Armenia S, Shaughnessy M, Greig C, Cowles R. Potentiation of serotonin signaling leads to increased carbohydrate and lipid absorption in the murine small intestine. J Pediatr Surg. 2019;54(6):1245–9.PubMedCrossRef
26.
go back to reference Penumatsa K, Fanburg B. Transglutaminase 2-mediated serotonylation in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014;306(4):L309–15.PubMedCrossRef Penumatsa K, Fanburg B. Transglutaminase 2-mediated serotonylation in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014;306(4):L309–15.PubMedCrossRef
27.
go back to reference Miyoshi N, Ishii H, Mimori K, Tanaka F, Hitora T, Tei M, et al. TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer. Ann Surg Oncol. 2010;17(4):967–72.PubMedCrossRef Miyoshi N, Ishii H, Mimori K, Tanaka F, Hitora T, Tei M, et al. TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer. Ann Surg Oncol. 2010;17(4):967–72.PubMedCrossRef
28.
go back to reference Liu H, Li Y, Li J, Liu Y, Cui B. H3K4me3 and Wdr82 are associated with tumor progression and a favorable prognosis in human colorectal cancer. Oncol Lett. 2018;16(2):2125–34.PubMedPubMedCentral Liu H, Li Y, Li J, Liu Y, Cui B. H3K4me3 and Wdr82 are associated with tumor progression and a favorable prognosis in human colorectal cancer. Oncol Lett. 2018;16(2):2125–34.PubMedPubMedCentral
29.
go back to reference Boroughs L, Antonyak M, Cerione R. A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival. J Biol Chem. 2014;289(14):10115–25.PubMedPubMedCentralCrossRef Boroughs L, Antonyak M, Cerione R. A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival. J Biol Chem. 2014;289(14):10115–25.PubMedPubMedCentralCrossRef
30.
31.
go back to reference Soll C, Jang J, Riener M, Moritz W, Wild P, Graf R, et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology (Baltimore, Md). 2010;51(4):1244–54.CrossRef Soll C, Jang J, Riener M, Moritz W, Wild P, Graf R, et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology (Baltimore, Md). 2010;51(4):1244–54.CrossRef
32.
go back to reference Jiang S, Li J, Dong F, Yang J, Liu D, Yang X, et al. Increased serotonin signaling contributes to the Warburg effect in pancreatic tumor cells under metabolic stress and promotes growth of pancreatic tumors in mice. Gastroenterology. 2017;153(1):277–291.e219.PubMedCrossRef Jiang S, Li J, Dong F, Yang J, Liu D, Yang X, et al. Increased serotonin signaling contributes to the Warburg effect in pancreatic tumor cells under metabolic stress and promotes growth of pancreatic tumors in mice. Gastroenterology. 2017;153(1):277–291.e219.PubMedCrossRef
33.
go back to reference Lee H, Eom C, Kwon Y, Ahn J, Kim S, Park S. Meta-analysis: selective serotonin reuptake inhibitors and colon cancer. Eur J Gastroenterol Hepatol. 2012;24(10):1153–7.PubMedCrossRef Lee H, Eom C, Kwon Y, Ahn J, Kim S, Park S. Meta-analysis: selective serotonin reuptake inhibitors and colon cancer. Eur J Gastroenterol Hepatol. 2012;24(10):1153–7.PubMedCrossRef
34.
go back to reference Zhang Y, Zhou T, Duan J, Xiao Z, Li G, Xu F. Inhibition of P-glycoprotein and glutathione S-transferase-pi mediated resistance by fluoxetine in MCF-7/ADM cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2013;67(8):757–62.CrossRef Zhang Y, Zhou T, Duan J, Xiao Z, Li G, Xu F. Inhibition of P-glycoprotein and glutathione S-transferase-pi mediated resistance by fluoxetine in MCF-7/ADM cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2013;67(8):757–62.CrossRef
35.
go back to reference Peer D, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004;64(20):7562–9.PubMedCrossRef Peer D, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004;64(20):7562–9.PubMedCrossRef
36.
go back to reference Peer D, Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006;237(2):180–7.PubMedCrossRef Peer D, Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006;237(2):180–7.PubMedCrossRef
37.
go back to reference Drinberg V, Bitcover R, Rajchenbach W, Peer D. Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine. Cancer Lett. 2014;354(2):290–8.PubMedCrossRef Drinberg V, Bitcover R, Rajchenbach W, Peer D. Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine. Cancer Lett. 2014;354(2):290–8.PubMedCrossRef
38.
go back to reference Hallett R, Girgis-Gabardo A, Gwynne W, Giacomelli A, Bisson J, Jensen J, et al. Serotonin transporter antagonists target tumor-initiating cells in a transgenic mouse model of breast cancer. Oncotarget. 2016;7(33):53137–52.PubMedPubMedCentralCrossRef Hallett R, Girgis-Gabardo A, Gwynne W, Giacomelli A, Bisson J, Jensen J, et al. Serotonin transporter antagonists target tumor-initiating cells in a transgenic mouse model of breast cancer. Oncotarget. 2016;7(33):53137–52.PubMedPubMedCentralCrossRef
39.
go back to reference Di Rosso M, Sterle H, Cremaschi G, Genaro A. Beneficial effect of fluoxetine and sertraline on chronic stress-induced tumor growth and cell dissemination in a mouse model of lymphoma: crucial role of antitumor immunity. Front Immunol. 2018;9:1341.PubMedPubMedCentralCrossRef Di Rosso M, Sterle H, Cremaschi G, Genaro A. Beneficial effect of fluoxetine and sertraline on chronic stress-induced tumor growth and cell dissemination in a mouse model of lymphoma: crucial role of antitumor immunity. Front Immunol. 2018;9:1341.PubMedPubMedCentralCrossRef
40.
go back to reference Jiang X, Lu W, Shen X, Wang Q, Lv J, Liu M, et al. Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy. JCI Insight. 2018;3(11):e98921.PubMedCentralCrossRef Jiang X, Lu W, Shen X, Wang Q, Lv J, Liu M, et al. Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy. JCI Insight. 2018;3(11):e98921.PubMedCentralCrossRef
41.
go back to reference Chinnapaka S, Bakthavachalam V, Munirathinam G. Repurposing antidepressant sertraline as a pharmacological drug to target prostate cancer stem cells: dual activation of apoptosis and autophagy signaling by deregulating redox balance. Am J Cancer Res. 2020;10(7):2043–65.PubMedPubMedCentral Chinnapaka S, Bakthavachalam V, Munirathinam G. Repurposing antidepressant sertraline as a pharmacological drug to target prostate cancer stem cells: dual activation of apoptosis and autophagy signaling by deregulating redox balance. Am J Cancer Res. 2020;10(7):2043–65.PubMedPubMedCentral
42.
go back to reference MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 2001;7(1):1–24.PubMedPubMedCentralCrossRef MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 2001;7(1):1–24.PubMedPubMedCentralCrossRef
Metadata
Title
Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment
Authors
Di Ye
Huanji Xu
Hongwei Xia
Chenliang Zhang
Qiulin Tang
Feng Bi
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-01971-1

Other articles of this Issue 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine